Investigational drug · Phase 2
ND-003
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Idiopathic Pulmonary Fibrosis (IPF).
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "ND-003"
First trial start
2026
Aug 18, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ND-003", any sponsor or status.
Conditions studied
As listed on its trial records.
- Idiopathic Pulmonary Fibrosis (IPF)
Approved drugs for the same conditions: Idiopathic pulmonary fibrosis · Respiratory
Largest trials
Live from ClinicalTrials.gov: studies naming "ND-003" as an intervention, largest first.
- A Study to Evaluate Safety, Tolerability and Pharmacokinetic of ND-003 Tablets in Healthy AdultsPivotal-lookingStatus unknown
Shenzhen NewDEL Biotech, Co., LtdIndustry
NCT06360874 · 104 participants (planned) · Start May 9, 2024 · Primary completion Dec 2024
Drug: ND-003 40mg; ND-003 placebo 40mg and 16 more · For: Healthy
Sites: Wuhan, China
- An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of ND-003 in Patients With Advanced Solid CancersEnrolling by invitation
Shenzhen NewDEL Biotech, Co., LtdIndustry
NCT06169579 · 96 participants (planned) · Start Feb 4, 2024 · Primary completion Jun 2028
Drug: ND-003 tablets; ND-003 tablets and 6 more · For: Advanced Solid Tumor
Sites: Xiamen, China; Lanzhou, China; Guangzhou, China · 21 sites in all
- A Phase Ⅱa Study of ND-003 Tablets in Patients With Idiopathic Pulmonary FibrosisEnrolling by invitation
Shenzhen NewDEL Biotech, Co., LtdIndustry
NCT07929948 · 10 participants (planned) · Start Aug 18, 2026 · Primary completion Jun 30, 2028
Drug: ND-003 Tablets · For: Idiopathic Pulmonary Fibrosis (IPF)
Sites: Guangzhou, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Idiopathic Pulmonary Fibrosis (IPF)
- HSK44459Phase 39 trials
Haisco Pharmaceutical Group Co., Ltd. · Psoriasis, Idiopathic Pulmonary Fibrosis (IPF), Progressive Pulmonary Fibrosis
- HEC585Phase 33 trials
Sunshine Lake Pharma Co., Ltd. · Progressive Fibrosing Interstitial Lung Disease (PF-ILD) / Progressive Pulmonary Fibrosis (PPF), Idiopathic Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis (IPF)
- DeupirfenidonePhase 32 trials
PureTech · Idiopathic Pulmonary Fibrosis (IPF), Idiopathic Pulmonary Fibrosis
- INS018_055Phase 32 trials
InSilico Medicine Hong Kong Limited · Idiopathic Pulmonary Fibrosis (IPF), Idiopathic Pulmonary Fibrosis
- TDI01Phase 32 trials
Beijing Tide Pharmaceutical Co., Ltd · GVHD, Chronic, Idiopathic Pulmonary Fibrosis (IPF)
- AK3280Phase 31 trial
Shanghai Ark Biopharmaceutical Co., Ltd. · Idiopathic Pulmonary Fibrosis (IPF)
- HB0056Phase 22 trials
Shanghai Huaota Biopharmaceutical Co., Ltd. · Asthma, Idiopathic Pulmonary Fibrosis (IPF)
- AGMB-447Phase 21 trial
Agomab Spain S.L.U. · Idiopathic Pulmonary Fibrosis (IPF)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.